Impact of proton pump inhibitor use on the comparative effectiveness and safety of prasugrel versus clopidogrel: Insights from the treatment with adenosine diphosphate receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome (translate-acs) study

Larry R. Jackson, Eric D. Peterson, Lisa A. McCoy, Christine Ju, Marjorie Zettler, Brian A. Baker, John C. Messenger, Douglas E. Faries, Mark B. Effron, David J. Cohen, Tracy Y. Wang

Research output: Contribution to journalArticlepeer-review

Abstract

Background--Proton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism. We sought to understand the comparative effectiveness and safety of prasugrel versus clopidogrel in the context of proton pump inhibitor (PPI) use. Methods and Results--Using data on 11 955 acute myocardial infarction (MI) patients treated with percutaneous coronary intervention at 233 hospitals and enrolled in the TRANSLATE-ACS study, we compared whether discharge PPI use altered the association of 1-year adjusted risks of major adverse cardiovascular events (MACE; death, MI, stroke, or unplanned revascularization) and Global Use of Strategies To Open Occluded Arteries (GUSTO) moderate/severe bleeding between prasugreland clopidogrel-treated patients. Overall, 17% of prasugrel-treated and 19% of clopidogrel-treated patients received a PPI at hospital discharge. At 1 year, patients discharged on a PPI versus no PPI had higher risks of MACE (adjusted hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.21-1.58) and GUSTO moderate/severe bleeding (adjusted HR 1.55, 95% CI 1.15-2.09). Risk of MACE was similar between prasugrel and clopidogrel regardless of PPI use (adjusted HR 0.88, 95% CI 0.62-1.26 with PPI, adjusted HR 1.07, 95% CI 0.90-1.28 without PPI, interaction P=0.31). Comparative bleeding risk associated with prasugrel versus clopidogrel use differed based on PPI use but did not reach statistical significance (adjusted HR 0.73, 95% CI 0.36-1.48 with PPI, adjusted HR 1.34, 95% CI 0.79-2.27 without PPI, interaction P=0.17). Conclusions--PPIs did not significantly affect the MACE and bleeding risk associated with prasugrel use, relative to clopidogrel.

Original languageEnglish (US)
Article numbere003824
JournalJournal of the American Heart Association
Volume5
Issue number10
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Keywords

  • Bleeding risk
  • Clopidogrel
  • Major adverse cardiovascular events
  • Prasugrel
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Impact of proton pump inhibitor use on the comparative effectiveness and safety of prasugrel versus clopidogrel: Insights from the treatment with adenosine diphosphate receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome (translate-acs) study'. Together they form a unique fingerprint.

Cite this